Omeros (NASDAQ:OMER) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Omeros (NASDAQ:OMER) in a report released on Tuesday,Benzinga reports. The brokerage currently has a $36.00 price target on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the stock. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Friday, January 17th. StockNews.com downgraded Omeros from a “hold” rating to a “sell” rating in a report on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Performance

NASDAQ OMER opened at $7.91 on Tuesday. The company’s 50-day simple moving average is $8.64 and its two-hundred day simple moving average is $7.61. Omeros has a one year low of $2.61 and a one year high of $13.60. The company has a market capitalization of $458.38 million, a price-to-earnings ratio of -3.42 and a beta of 2.03.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Omeros by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock valued at $314,000 after acquiring an additional 1,110 shares in the last quarter. Truvestments Capital LLC grew its stake in Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 1,972 shares during the last quarter. Ameriprise Financial Inc. increased its position in Omeros by 2.0% during the 4th quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company’s stock valued at $1,190,000 after buying an additional 2,317 shares in the last quarter. Finally, Cerity Partners LLC raised its stake in Omeros by 9.9% in the fourth quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 2,600 shares during the last quarter. Institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.